Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) Equity Ratio (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Equity Ratio for 12 consecutive years, with 0.63 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 4.78% year-over-year to 0.63, compared with a TTM value of 0.63 through Sep 2025, down 4.78%, and an annual FY2024 reading of 0.46, down 28.58% over the prior year.
  • Equity Ratio was 0.63 for Q3 2025 at Arcadia Biosciences, up from 0.58 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.78 in Q1 2022 and bottomed at 0.46 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.66, with a median of 0.66 recorded in 2023.
  • The sharpest move saw Equity Ratio skyrocketed 91.69% in 2021, then fell 29.58% in 2023.
  • Year by year, Equity Ratio stood at 0.71 in 2021, then grew by 1.73% to 0.72 in 2022, then decreased by 10.79% to 0.64 in 2023, then fell by 28.58% to 0.46 in 2024, then surged by 37.73% to 0.63 in 2025.
  • Business Quant data shows Equity Ratio for RKDA at 0.63 in Q3 2025, 0.58 in Q2 2025, and 0.69 in Q1 2025.